Research location

Concord

California, United States

Published trials278

Site observations282

Linked trials published278

Page1 / 6

Research activity in Concord

California, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 278 trials and 282 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Concord

278 linked trials · page 1 of 6

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · 2026-08-24 · 1 site observation

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979 · 2026-08-04 · 1 site observation

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135 · 2026-07-06 · 1 site observation

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart FailureNCT05677100 · 2023-08-23 · 1 site observation

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18 · 1 site observation

Assessment of CCM in HF With Higher Ejection FractionNCT05064709 · 2022-02-03 · 1 site observation

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199 · 2025-08-11 · 1 site observation

ACTIVE_NOT_RECRUITING

SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 DiabetesNCT06719531 · 2025-05-01 · 1 site observation

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · 2024-11-05 · 1 site observation

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 · 2024-04-01 · 1 site observation

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)NCT06269107 · 2024-02-15 · 1 site observation

A Study of CT-868 in Type 1 Diabetes MellitusNCT06062069 · 2023-10-19 · 1 site observation

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 · 2023-09-27 · 1 site observation

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityNCT06037252 · 2023-09-21 · 1 site observation

ACTIVE_NOT_RECRUITING

Addressing Diabetes by Elevating Access to NutritionNCT05228860 · 2023-09-18 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation

ACTIVE_NOT_RECRUITING

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · 2023-02-01 · 1 site observation

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightNCT05649137 · 2023-01-04 · 1 site observation

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation

ACTIVE_NOT_RECRUITING

Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility StudyNCT05594940 · 2022-09-21 · 1 site observation

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)NCT05514535 · 2022-08-29 · 1 site observation

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection TherapyNCT05463744 · 2022-08-12 · 1 site observation

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin IcodecNCT05352815 · 2022-06-01 · 1 site observation

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)NCT05259033 · 2022-04-11 · 1 site observation

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal InsulinNCT05275400 · 2022-03-08 · 1 site observation

Confocal Laser Endomicroscopy Nodule Localization by Robotic BronchoscopyNCT05231278 · 2022-01-20 · 1 site observation

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesNCT05051579 · 2021-09-29 · 1 site observation

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNCT04916470 · 2021-06-15 · 1 site observation

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)NCT04880850 · 2021-05-14 · 1 site observation

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)NCT04848480 · 2021-04-30 · 1 site observation

LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.NCT04790344 · 2021-03-20 · 1 site observation

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)NCT04605991 · 2020-11-04 · 1 site observation

A Study of LY3209590 in Participants With Type 1 DiabetesNCT04450407 · 2020-07-06 · 1 site observation

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightNCT04184622 · 2019-12-04 · 1 site observation

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseNCT03819153 · 2019-06-17 · 2 site observations

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin GlargineNCT03874715 · 2019-03-11 · 1 site observation

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump TherapyNCT03830281 · 2019-02-14 · 1 site observation

Establishment of a PDT Patient RegistryNCT03589456 · 2019-01-18 · 1 site observation

PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 DaysNCT03808376 · 2018-12-27 · 1 site observation

A Study of LY3209590 in Participants With Type 2 Diabetes MellitusNCT03736785 · 2018-11-15 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.